FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983650417> ?p ?o ?g. }

• W1983650417 endingPage "997" @default.
• W1983650417 startingPage "992" @default.
• W1983650417 abstract "A phase I study was performed in 21 patients with previously untreated, locally inoperable, non-small-cell lung cancer (NSCLC) with ambulatory continuous carboplatin infusion together with continuous thoracic irradiation over 6 weeks. A dose range for carboplatin of 15 mg m-2 day-1 during the last 21 days (first level), during the last 31 days (second level), or during 6 weeks of the radiation period (third level) and thereafter 20 or 25 mg m-2 day-1 during 6 weeks of radiation (fourth and fifth level) was used. The total radiation dose was 60 Gy given as 2 Gy day-1 for 5 days week-1. The first three patients received radiotherapy without carboplatin. WHO grade III/IV leucopenia and thrombocytopenia occurred in the last two dose levels in two out of six and one out of six patients with 20 mg m-2 day-1 respectively, and in all three patients with 25 mg m-2 day-1 (dose-limiting toxicity). One local infection around the port and a subclavian vein thrombosis occurred. Radiation toxicity of the lung and oesophagus did not seem to be influenced by carboplatin treatment. Out of 21 patients one had a complete response (CR), ten partial response (PR), six stable disease (SD) and four progressive disease (PD). Total (TPt) and ultrafilterable plasma platinum (UPt) were measured in the last three dose levels with atomic absorption spectrophotometry with Zeeman correction. The mean (s.d.) level for TPt for 6 weeks at 15, 20 and 25 mg m-2 day-1 was 0.76 (0.15), 0.78 (0.19) and 0.90 (0.22) mg l-1 for UPt 0.10 (0.03), 0.12 (0.02) and 0.20 (0.03) mg l-1 respectively. TPt concentration levelled off after 3 weeks. The mean (s.d.) CLTB for UPt was 281 +/- 21 ml min-1 and correlated with glomerular filtration rate (r = 0.61, P = 0.03). As estimated with the sigmoid Emax model defined by the Hill equation the percentage reduction in platelets correlated with the area under the curve for UPt (r = 0.77). The maximum tolerable dose of carboplatin with concomitant continuous 60 Gy radiotherapy is 25 mg m-2 day-1; the recommended dose for phase II or III studies is 20 mg m-2 day-1 day for 6 weeks." @default.
• W1983650417 created "2016-06-24" @default.
• W1983650417 creator A5014311522 @default.
• W1983650417 creator A5016301942 @default.
• W1983650417 creator A5049567969 @default.
• W1983650417 creator A5068253914 @default.
• W1983650417 creator A5080104215 @default.
• W1983650417 creator A5086412405 @default.
• W1983650417 date "1995-10-01" @default.
• W1983650417 modified "2023-10-09" @default.
• W1983650417 title "Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study" @default.
• W1983650417 cites W133997601 @default.
• W1983650417 cites W1550111394 @default.
• W1983650417 cites W1757385007 @default.
• W1983650417 cites W1764040454 @default.
• W1983650417 cites W1978156658 @default.
• W1983650417 cites W1979497535 @default.
• W1983650417 cites W1982789959 @default.
• W1983650417 cites W2005750330 @default.
• W1983650417 cites W2015984182 @default.
• W1983650417 cites W2016829401 @default.
• W1983650417 cites W2034801847 @default.
• W1983650417 cites W2051767374 @default.
• W1983650417 cites W2061961646 @default.
• W1983650417 cites W2072659822 @default.
• W1983650417 cites W2073879537 @default.
• W1983650417 cites W2078822778 @default.
• W1983650417 cites W2080684511 @default.
• W1983650417 cites W2090704952 @default.
• W1983650417 cites W2093039348 @default.
• W1983650417 cites W2112985694 @default.
• W1983650417 cites W2116812161 @default.
• W1983650417 cites W2119171109 @default.
• W1983650417 cites W2124671236 @default.
• W1983650417 cites W2138945505 @default.
• W1983650417 cites W2159577139 @default.
• W1983650417 cites W2226077283 @default.
• W1983650417 cites W2262649774 @default.
• W1983650417 cites W2302401384 @default.
• W1983650417 cites W2312703485 @default.
• W1983650417 cites W2317448174 @default.
• W1983650417 cites W2320191339 @default.
• W1983650417 cites W2398323629 @default.
• W1983650417 cites W2413182551 @default.
• W1983650417 cites W2440265926 @default.
• W1983650417 cites W2442700905 @default.
• W1983650417 cites W2443193704 @default.
• W1983650417 doi "https://doi.org/10.1038/bjc.1995.448" @default.
• W1983650417 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2034056" @default.
• W1983650417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7547255" @default.
• W1983650417 hasPublicationYear "1995" @default.
• W1983650417 type Work @default.
• W1983650417 sameAs 1983650417 @default.
• W1983650417 citedByCount "15" @default.
• W1983650417 countsByYear W19836504172022 @default.
• W1983650417 crossrefType "journal-article" @default.
• W1983650417 hasAuthorship W1983650417A5014311522 @default.
• W1983650417 hasAuthorship W1983650417A5016301942 @default.
• W1983650417 hasAuthorship W1983650417A5049567969 @default.
• W1983650417 hasAuthorship W1983650417A5068253914 @default.
• W1983650417 hasAuthorship W1983650417A5080104215 @default.
• W1983650417 hasAuthorship W1983650417A5086412405 @default.
• W1983650417 hasBestOaLocation W19836504172 @default.
• W1983650417 hasConcept C112705442 @default.
• W1983650417 hasConcept C126322002 @default.
• W1983650417 hasConcept C126894567 @default.
• W1983650417 hasConcept C141071460 @default.
• W1983650417 hasConcept C2776256026 @default.
• W1983650417 hasConcept C2776694085 @default.
• W1983650417 hasConcept C2778239845 @default.
• W1983650417 hasConcept C2781451048 @default.
• W1983650417 hasConcept C29730261 @default.
• W1983650417 hasConcept C2989005 @default.
• W1983650417 hasConcept C509974204 @default.
• W1983650417 hasConcept C71924100 @default.
• W1983650417 hasConcept C90924648 @default.
• W1983650417 hasConceptScore W1983650417C112705442 @default.
• W1983650417 hasConceptScore W1983650417C126322002 @default.
• W1983650417 hasConceptScore W1983650417C126894567 @default.
• W1983650417 hasConceptScore W1983650417C141071460 @default.
• W1983650417 hasConceptScore W1983650417C2776256026 @default.
• W1983650417 hasConceptScore W1983650417C2776694085 @default.
• W1983650417 hasConceptScore W1983650417C2778239845 @default.
• W1983650417 hasConceptScore W1983650417C2781451048 @default.
• W1983650417 hasConceptScore W1983650417C29730261 @default.
• W1983650417 hasConceptScore W1983650417C2989005 @default.
• W1983650417 hasConceptScore W1983650417C509974204 @default.
• W1983650417 hasConceptScore W1983650417C71924100 @default.
• W1983650417 hasConceptScore W1983650417C90924648 @default.
• W1983650417 hasIssue "4" @default.
• W1983650417 hasLocation W19836504171 @default.
• W1983650417 hasLocation W19836504172 @default.
• W1983650417 hasLocation W19836504173 @default.
• W1983650417 hasLocation W19836504174 @default.
• W1983650417 hasOpenAccess W1983650417 @default.
• W1983650417 hasPrimaryLocation W19836504171 @default.
• W1983650417 hasRelatedWork W1983784941 @default.
• W1983650417 hasRelatedWork W2049284535 @default.

• next